4.6 Review

Immunotherapeutic targets in non-small cell lung cancer

Journal

IMMUNOLOGY
Volume 168, Issue 2, Pages 256-272

Publisher

WILEY
DOI: 10.1111/imm.13562

Keywords

immunotherapy; non-small cell lung cancer; NSCLC; TME; tumour microenvironment

Categories

Ask authors/readers for more resources

This review discusses the immunotherapeutic targets in non-small cell lung cancer (NSCLC) tumors and how the tumor microenvironment (TME) can influence the response to immunotherapy.
Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5-year survival rate of similar to 20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in-depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available